Arctic Aurora LifeScience HRegister to Unlock Ratings |
Performance History | 31/08/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 8.6 | 3.2 | -2.3 | -0.9 | 12.9 | |
+/-Cat | - | - | - | - | - | |
+/-B’mrk | - | - | - | - | - | |
Category: Other Equity | ||||||
Category Benchmark: - |
Key Stats | ||
NAV 25/09/2024 | NOK 1962.92 | |
Day Change | -1.11% | |
Morningstar Category™ | Other Equity | |
ISIN | IE00BDHFW354 | |
Fund Size (Mil) 31/08/2024 | NOK 2654.99 | |
Share Class Size (Mil) 31/08/2024 | NOK 181.77 | |
Max Initial Charge | - | |
Ongoing Charge 29/12/2023 | 1.16% |
Investment Objective: Arctic Aurora LifeScience H |
The investment objective is to achieve long-term capital appreciation through global equity investments within the pharmaceuticals, biotechnology and life science sectors. The team has more than 50 years of experience from the industry, and will utilize their know-how to pick the early winners in a fast developing life science and biotech space. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Ulrica Bjerke 27/05/2016 | ||
Daniel Bolanowski 01/06/2021 | ||
Inception Date 30/06/2016 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Pharma Bio&Life NR NOK | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Arctic Aurora LifeScience H | 31/07/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 8.26 |
Novo Nordisk A/S Class B | Healthcare | 7.39 |
AstraZeneca PLC | Healthcare | 5.89 |
Merck & Co Inc | Healthcare | 3.52 |
Daiichi Sankyo Co Ltd ADR | Healthcare | 3.01 |
Increase Decrease New since last portfolio | ||
Arctic Aurora LifeScience H |